Journals / MN Kardiyoloji / 2005 / Cilt: 12 - Sayı: 4

Aspirin resistance

Aspirin direnci

Pages
300–304
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Aspirin resistance is responsible for the apperance of the acute coronary syndrome even though aspirin had been used.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aspirin is the most widely consumed drug in medicine due to analgesic, anti-inflammatory and antipyretic effect.
📊
Key Findings & Data:This way it prevents the formation of TxA 2 which is the strong mediator of the platelet aggregation.
💡
Conclusion & Impact:Aspirin resistance is responsible for the apperance of the acute coronary syndrome even though aspirin had been used.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kan trombositleri · Tromboz · Aspirin

Abstract

Aspirin is the most widely consumed drug in medicine due to analgesic, anti-inflammatory and antipyretic effect. Aspirin is the irreversible inhibitor of the cyclooxygenase enzyme. This way it prevents the formation of TxA 2 which is the strong mediator of the platelet aggregation. At the basis of events such as the unstable angina pectoris, sudden cardiac death, acute MI or stroke, is the platelet activation which develops after plaque rupture. Aspirin use is fundamental in the secondary prevention of all cardiovascular disease, stroke and peripheric vascular disease. Aspirin resistance is responsible for the apperance of the acute coronary syndrome even though aspirin had been used.

Özet

Ağrı kesici, antiinflamatuvar ve ateş düşürücü etkisi nedeni ile aspirin en çok kullanılan ilaçtır. Aspirin siklooksijenaz enziminin geri dönüşümsüz inhibitörüdür. Bu yolla platelret agregasyonunun güçlü mediyatörü olan TxA 2'nin oluşmasını önler. Kararsız angina, ani kalp ölümü, AMİ veya inme gibi olayların temelinde plak yırtılması sonrası gelişen trombosit aktivasyonu vardır. Aspirin trombosit agregasyon ve adezyonunu önleyerek trombüs oluşumunu bloke eder. İskemik kalp hastalığı, inme ve periferik damar hastalığı olmak üzere tüm kardiyovasküler hastalıkların ikincil korunmasında aspirin kullanılmaktadır. Aspirin kullanılmasına rağmen akut arteryel trombotik olay gelişimine, aspirin direnci denilmektedir.

🔖

Cite This Article

BİTİGEN, A., KARAKAYA, O., SAĞLAM, M., KAHVECİ, G. (2005). Aspirin resistance. MN Kardiyoloji, Cilt: 12 - Sayı: 4, 300–304. https://ajindex.com/articles/297979

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Patrano C; Aspirin as an antiplatelet drug, N Eng J Med 1994; 330:1287-94
  2. Antiplatelet Trialists' Collaboration.Secondory prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988;296:320-31
  3. Trialist Collaboration, Antiplatelet Collaborative overwiew of randomised trials of antiplatelet therapy-l: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet the­rapy in variosus categories of patients. BMJ 1994; 308:81-106
  4. Thrombosis Prevention Trial: Randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk.The Medical Research Council's General Practice Research Framework. Lancet 1998; 351:233-41
  5. Final Report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Healt Study Research Group. N Engl J Med 1989; 321:129-35
  6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and lowe-dose aspirin in patients with hypertension: Prihcipal resuts of the Hypertension Optimal Treatment (HOT) randomised trial HOT Study Group, ncet 1998; 351:1755-62
  7. Peto R, Gray R, Collins R, et al. Randomised trial of Dphylactic daily aspirin in British male doctors. BMJ 1988; 6:313-6
  8. ISIS-2 (Second International Study of Infarct Survival) Colaborative Group: Randomized trial of intravenous streptokinase, al aspirin, both, or neither among 17.187 caves of suspected ute myocardial infarction: ISIS-2 Lancet 1988; 2:349-60
  9. Schwartz L, Bourassa M, Lesperance J et al. Aspirin and diridamole in the prevention of restenosis after percutaneous nsluminal coronary angioplast. N Engl J Med 1988; 318:1714-9
  10. Ferguson J, Doughety K, et al: Relation between procedural tivating clotting time and outcome after percutaneous translunal coronary angioplasty. J Am Coll Cardiol 1994; 23:1061-5
  11. Nanns CR, Hillegass WB Jr, Nelson CL, et al. Relation itween activating clotting time during angioplasty and abrupt )sure. Circulation 1996; 93:667-71
  12. White C, Chitman B, Lassar T, et al. Antiplatelet agents are fective in reducing the immediate complications of PTCA. îsults of the ticlopidine multicenter trail (abstract) circulation I87; 76 (suppl 4):400
  13. PopmaJJ, Weitz J, Bitti JA, et al. Antithrombotic therapy in itients undergoing coronary angiplasty. Chest 1998; 114( ippl):728-41. 14. kThe PURSUIT Trail Investigators. Inhib